Drosophila melanogaster as a model organism for invasive aspergillosis

Methods in Molecular Biology

Volumn 845, Issue , 2012, Pages 455-468

  Lionakis, Michail S ^a   Kontoyiannis, Dimitrios P ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antifungal efficacy; Aspergillosis; Aspergillus; Drosophila; Fruit fly; Invertebrate mini host model; Pathogenesis; Virulence

Indexed keywords

ANTIFUNGAL AGENT;

ANIMAL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG EFFECT; GENETICS; IMMUNOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; DROSOPHILA MELANOGASTER; INVERTEBRATA; MAMMALIA; VERTEBRATA;

EID: 84858133600     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-539-8_32     Document Type: Chapter

References (42)

1. Kontoyiannis DP, Marr KA, Park BJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50:1091–1100.
2. Ben-Ami R, Lewis RE and Kontoyiannis DP (2009) Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 22:376–384.
3. Kontoyiannis DP and Lewis RE (2003) Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Update 6:257–269.
4. Pfaller MA and Rinaldi MG (1993) Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am 2:435–444.
5. Lionakis MS, Lewis RE, Chamilos G and Kontoyiannis DP (2005) Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 25:1174–1180.
6. Lewis RE, Prince RA, Chi J and Kontoyiannis DP (2002) Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208–3214.
7. Petraitis V, Petraitiene R, Lin P et al (2005) Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 49: 1642–1645.
8. van de Sande WW, Mathot RA, ten Kate MT et al (2009) Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidula-fungin. Antimicrob Agents Chemother 53:2005–2013.
9. Vallor AC, Kirkpatrick WR, Najvar LK et al (2008) Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother 52:2593–2598.
10. Nierman WC, Pain A, Anderson MJ et al (2005) Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 438:1151–1156.
11. Schrettl M, Bignell E, Kragl C et al (2004) Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J Exp Med 200: 1213–1219.
12. Schrettl M, Bignell E, Kragl C et al (2007) Distinct roles for intra-and extracellular sidero-phores during Aspergillus fumigatus infection. PLoS Pathog 3:1195–1207.
13. Tsai HF, Chang YC, Washburn RG, Wheeler MH and Kwon-Chung KJ (1998) The devel-opmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol 180: 3031–3038.
14. Spikes S, Xu R, Nguyen CK, Chamilos G et al (2008) Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 197:479–486.
15. Brown JS, Aufauvre-Brown A, Brown J, Jennings JM, Arst H Jr and Holden DW (2000) Signature-tagged and directed mutagenesis identify PABA synthetase as essential for Aspergillus fumigatus pathogenicity. Mol Microbiol 36:1371–1380.
16. Bhabhra R, Miley MD, Mylonakis E et al (2004) Disruption of the Aspergillus fumigatus gene encoding nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. Infect Immun 72:4731–4740.
17. Panepinto JC, Oliver BG, Fortwendel JR, Smith DL, Askew DS and Rhodes JC (2003) Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of Invasive pulmonary aspergillosis. Infect Immun 71:2819–2826.
18. Krappmann S, Bignell EM, Reichard U, Rogers T, Haynes K and Braus GH (2004) The Aspergillus fumigatus transcriptional activator CpcA contributes significantly to the virulence of this fungal pathogen. Mol Microbiol 52:785–799.
19. Lemaitre B, Nicolas E, Michaut L, Reichhart JM and Hoffmann JA (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86:973–983.
20. Lemaitre B, Reichhart JM and Hoffmann JA (1997) Drosophila host defense: differential expression of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci USA 94:14614–14619.
21. Apidianakis Y, Rahme LG, Heitman J, Ausubel FM, Calderwood SB and Mylonakis E (2004) Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response Eukaryot Cell 3:413–419.
22. Mylonakis E, Casadevall A and Ausubel FM (2007) Exploiting amoeboid and non-ver-tebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog 3:e101.
23. Alarco AM, Marcil A, Chen J, Suter B, Thomas D and Whiteway M (2004) Immune-deficient Drosophila melanogaster: a model for the innate immune response to human fungal pathogens. J Immunol 172:5622–5628.
24. Mylonakis E, Ausubel FM, Perfect JR, Heitman J and Calderwood SB (2002) Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci USA 99:15675–15680.
25. Mylonakis E, Moreno R, El Khoury JB et al (2005) Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 73:3842–3850.
26. Steenbergen JN, Shuman HA and Casadevall A (2001) Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci USA 98:15245–15250.
27. Steenbergen JN, Nosanchuk JD, Maliaris SD and Casadevall A (2003) Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoi-deum. Infect Immun 71:4862–4872.
28. De Gregorio E, Spellman PT, Rubin GM and Lemaitre B (2001) Genome-wide analysis of the Drosophila immune response by using oli-gonucleotide microarrays. Proc Natl Acad Sci USA 98:12590–12599.
29. Brennan CA and Anderson KV (2004) Drosophila: the genetics of innate immune recognition and response. Annu Rev Immunol 22:457–483.
30. Hoffmann JA and Reichhart JM (2002) Drosophila innate immunity: an evolutionary perspective. Nat Immunol 3:121–126.
31. De Gregorio E, Spellman PT, Tzou P, Rubin GM and Lemaitre B (2002) The Toll and Imd pathways are the major regulators of the immune response in Drosophila . EMBO J 21: 2568–2579.
32. Lionakis MS, Lewis RE, May GS et al (2005) Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis 191: 1188–1195.
33. Ben-Ami R, Lamaris GA, Lewis RE and Kontoyiannis DP (2010) Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Med Mycol 48:310–317.
34. Chamilos G, Lewis RE, Hu J et al (2008) Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA. 105:9367–9372.
35. Pongas GN, Ben-Ami R, Lewis RE, Walsh TJ and Kontoyiannis DP (2009) Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis. Antimicrob Agents Chemother 53:4569.
36. Lamaris GA, Chamilos G, Lewis RE and Kontoyiannis DP (2007) Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. J Infect Dis 196: 1860–1864.
37. Chamilos G, Lionakis MS, Lewis RE et al (2006) Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 193:1014–1022.
38. Lionakis MS and Kontoyiannis DP (2005) Fruit flies as a minihost model for studying drug activity and virulence in Aspergillus. Med Mycol 43 Suppl 1:S111-114.
39. Chamilos G, Bignell EM, Schrettl M et al (2010) Exploring the concordance of Aspergillus fumigatus pathogenicity in mice and Toll-deficient flies. Med Mycol 48:506–510.
40. Ryder NS and Leitner I (2001) Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 39:91–95.
41. Bowman JC, Abruzzo GK, Anderson JW et al (2001) Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45:3474–3481.
42. Kontoyiannis DP, Lionakis MS and Halder G (2004) Toll pathway in Drosophila melanogaster: A possible role to study the impact of immune senescence in poor responses against Aspergillus fumigatus. 14th Focus on Fungal Infections, New Orleans, LA, USA, Abstract # 31.